UroGen Pharma
URGN
74 hedge funds and large institutions have $497M invested in UroGen Pharma in 2019 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 38 increasing their positions, 10 reducing their positions, and 9 closing their positions.
280% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 10
209% more call options, than puts
Call options by funds: $1.38M | Put options by funds: $447K
122% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 9
20% more capital invested
Capital invested by funds: $413M → $497M (+$84.3M)
17% more funds holding
Funds holding: 63 → 74 (+11)
6.2% more ownership
Funds ownership: 59.54% → 65.73% (+6.2%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highline Capital Management
New York
|
+$22M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$20.1M |
| 3 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
+$19.1M |
| 4 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
+$14.8M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$12.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$8.58M |
| 2 |
PFO
Pathstone Family Office
Englewood,
New Jersey
|
-$1.67M |
| 3 |
MCM
McKinley Capital Management
Anchorage,
Alaska
|
-$726K |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$700K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$653K |
URGN Hedge Fund Activity: Q1 2019 in Review
74 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q1 2019, worth a combined $497M — up 20% from $413M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new URGN positions and 9 closed out — a net gain of 11 holders — while 38 added to existing stakes and 10 trimmed.
The largest buyer was Highline Capital Management, adding an estimated $22M. The largest seller was Citadel Advisors, cutting an estimated $8.58M.
- 74 institutional investors held UroGen Pharma (URGN) as of Q1 2019, up from 63 in Q4 2018.
- Funds reported $497M of UroGen Pharma stock for Q1 2019, up 20% quarter-over-quarter.
- 20 funds opened new UroGen Pharma positions in Q1 2019 and 9 closed out, a net change of +11 holders.
- The largest UroGen Pharma buyer in Q1 2019 was Highline Capital Management, an estimated $22M added.
- The largest UroGen Pharma seller in Q1 2019 was Citadel Advisors, an estimated $8.58M sold.
Based on aggregated 13F filings for Q1 2019.